List of Excipients in Branded Drug CERVIDIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Ferring Pharmaceuticals Inc	CERVIDIL	dinoprostone	55566-2800	POLYETHYLENE GLYCOL

CERVIDIL Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

CERVIDIL is a controlled-release vaginal insert containing 10 mg of dinoprostone, the prostaglandin E2 analogue used for cervical ripening in pregnant patients at or near term. Its commercial value is tied less to the active ingredient, which is an established generic API, than to the vaginal delivery system, release control, retrieval mechanism, stability profile, and hospital workflow.[1]

The strongest opportunities are a technically robust generic vaginal insert, differentiated controlled-release platforms, lower-cost manufacturing, and adjacent products that improve storage, administration, retrieval, or labor-induction logistics. The principal barriers are dose uniformity, release-rate control, vaginal tolerability, API stability, extractables and leachables, and clinical comparability.

What is CERVIDIL and how does its delivery system work?

CERVIDIL is a 10 mg dinoprostone vaginal insert indicated for cervical ripening in patients at or near term when induction of labor is medically indicated.[1] The insert is placed in the posterior vaginal fornix and releases dinoprostone at approximately 0.3 mg per hour under labeled conditions. The system is designed for removal when active labor begins, after membrane rupture, in the presence of uterine tachysystole or fetal distress, or before administration of oxytocin.[1]

CERVIDIL product profile

Attribute	CERVIDIL profile
Active ingredient	Dinoprostone
Strength	10 mg per vaginal insert
Dosage form	Controlled-release vaginal insert
Route	Vaginal
Release behavior	Approximately 0.3 mg/hour under labeled conditions
Indication	Cervical ripening at or near term
Administration	Placement in posterior vaginal fornix
Retrieval	Attached retrieval system
Sponsor	Ferring Pharmaceuticals
U.S. regulatory application	NDA 020656
Regulatory pathway	New drug application, with generic competition subject to FDA approval requirements

The formulation is a drug-device combination at the product level because the polymeric insert and retrieval system control delivery and removal. The commercial product must perform as a complete system, not merely as a source of dinoprostone.

What excipients are used in CERVIDIL?

CERVIDIL uses a hydrogel-based controlled-release delivery system. Public prescribing information describes the insert and its delivery mechanism but does not provide a complete quantitative formulation recipe suitable for direct reverse engineering.[1]

The excipient strategy can be analyzed by function:

Formulation function	Likely technical requirement	Commercial relevance
Polymer matrix	Controls hydration, diffusion, and dinoprostone release	Core generic-development risk
Hydrophilic carrier	Supports drug distribution and release in vaginal fluid	Affects dose uniformity and burst release
Structural support	Maintains insert integrity during handling and use	Controls insertion, retrieval, and patient safety
Retrieval component	Enables rapid removal by clinical staff	Essential to label-conforming use
Packaging system	Limits moisture, oxygen, and light exposure	Important for shelf life and hospital storage
Process aids	Support mixing, molding, drying, or assembly	Must be controlled for residuals and extractables

A generic developer should not assume that matching the named excipients will produce a therapeutically equivalent product. The critical performance attributes are polymer grade, molecular weight distribution, cross-link density, porosity, residual moisture, drug dispersion, insert geometry, and retrieval-system configuration.

What formulation attributes control CERVIDIL performance?

The most important attributes are:

1. Dinoprostone content uniformity.
2. Initial release or burst rate.
3. Total release over the labeled dwell period.
4. Polymer hydration rate.
5. Insert dimensional stability.
6. Mechanical integrity before and after hydration.
7. Retrieval force and retrieval completeness.
8. Local vaginal tolerability.
9. Moisture and oxygen sensitivity.
10. Package integrity throughout shelf life.

The release profile is particularly important. A formulation can meet assay specifications while failing to reproduce the clinical exposure pattern if the polymer swells too quickly, fractures, erodes, or releases dinoprostone unevenly.

What excipient strategy is appropriate for a CERVIDIL generic?

The lowest-risk strategy is a Q1/Q2-oriented formulation using excipients with established vaginal or oral regulatory precedents, combined with a polymer system that reproduces the reference product's release behavior. A Q1/Q2 approach means matching the same inactive ingredients qualitatively and quantitatively where feasible. That approach can reduce regulatory and clinical risk, but it may be difficult if the reference formulation's polymer specifications are proprietary or incompletely disclosed.

A second strategy uses an alternative polymer matrix with equivalent performance. This can lower manufacturing cost or improve robustness, but it creates a larger equivalence package. The developer may need comparative in vitro release data, mechanical testing, local tolerability data, and potentially clinical or pharmacodynamic evidence, depending on FDA expectations for the proposed product.

Recommended excipient-development priorities

Polymer selection

Candidate polymers should be evaluated for:

• Hydration in simulated vaginal fluid.
• Release-rate reproducibility.
• Low batch-to-batch variability.
• Compatibility with dinoprostone.
• Resistance to fragmentation.
• Low extractables and leachables.
• Manufacturability at commercial scale.

Hydrophilic polyethylene oxide or polyethylene glycol-related systems may be relevant to the reference product's hydrogel architecture, but a developer should distinguish between low-molecular-weight polyethylene glycol used as a processing or carrier component and high-molecular-weight polyethylene oxide used as a release-controlling polymer. Their regulatory and performance roles are different.

Moisture control

Moisture can alter polymer swelling, drug distribution, insert hardness, and release kinetics. The product should be developed around a moisture-controlled manufacturing and packaging process rather than treated as a conventional dry solid.

High-barrier unit-dose packaging is commercially important. A package that protects the insert from humidity while remaining easy for hospital staff to open can create value without changing the drug formulation.

API compatibility

Dinoprostone is sensitive to formulation and environmental conditions. Development should examine:

• Oxidative degradation.
• Moisture-mediated degradation.
• Drug-polymer interactions.
• Adsorption to processing equipment.
• Degradation during sterilization or terminal processing.
• Stability in the final package.

The preferred approach is aseptic or controlled nonsterile manufacture based on the product's validated microbiological requirements. Conventional terminal sterilization may be incompatible with dinoprostone stability or polymer performance and should not be presumed to be available.

What generic entry opportunities exist for CERVIDIL?

The principal U.S. opportunity is an ANDA for a generic dinoprostone vaginal insert. Because the product is a locally acting vaginal delivery system, the key challenge is demonstrating pharmaceutical equivalence and therapeutic equivalence through a combination of formulation similarity, in vitro release testing, and any additional studies required by FDA.[2]

Generic product opportunities

Opportunity	Value proposition	Main barrier
Standard 10 mg vaginal insert	Direct substitution for CERVIDIL	Release-rate and equivalence requirements
Lower-cost hospital product	Reduces induction-of-labor acquisition cost	Scale, quality, and supply reliability
Improved retrieval design	Faster removal and lower handling burden	Device comparability and human factors
Enhanced package format	Better storage and easier opening	Packaging validation
Hospital induction kit	Combines insert, applicator, and documentation	Combination-product and procurement complexity
Internationally adapted product	Supports markets with different procurement systems	Local registration and patent review
Alternative polymer insert	Potentially lower cost or stronger shelf life	Larger regulatory data package

A generic product with the same strength but a materially different release system may face a more difficult review than a close formulation match. The formulation must reproduce the clinically relevant exposure and permit rapid removal when required.

What is the FDA regulatory status of CERVIDIL?

CERVIDIL is an FDA-approved prescription product under NDA 020656.[1] Its active ingredient, dinoprostone, is established in obstetric use, but the specific controlled-release vaginal insert remains a complex dosage form.

The principal regulatory issues are:

• Pharmaceutical equivalence to the reference listed drug.
• Demonstration of equivalent release performance.
• Product quality under vaginal-use conditions.
• Local irritation and tolerability.
• Device and retrieval-system performance.
• Packaging and shelf-life validation.
• Labeling for removal, oxytocin use, and adverse uterine activity.

The FDA's product-specific guidance, if issued or updated for dinoprostone vaginal inserts, would be central to development planning. The Orange Book and FDA approval records are the controlling sources for reference-product designation, patent listings, therapeutic-equivalence ratings, and approved generic products.[2,3]

What patents protect CERVIDIL and when does exclusivity expire?

CERVIDIL was approved in the 1990s, so the original U.S. regulatory exclusivity period has expired. Any original composition, delivery-system, or method-of-use patents associated with the product would also be expected to have reached the end of their ordinary U.S. patent terms unless a later patent or patent-term adjustment applies.

The practical entry question is not whether early CERVIDIL exclusivity remains. It is whether any later, unexpired patents are listed for the reference product or could support litigation against an ANDA applicant.

Patent and exclusivity diligence

Issue	Relevance to CERVIDIL
Original product patent	Expected to be expired based on product age
FDA exclusivity	Historical exclusivity is expired
Orange Book-listed patents	Must be checked in the current FDA listing
Paragraph IV risk	Depends on any unexpired listed patent
Formulation patents	May cover polymer composition or release profile
Method-of-use patents	May cover induction or cervical-ripening use
Device patents	May cover retrieval or insert construction
Manufacturing patents	May affect process freedom to operate
Settlement agreements	No reliable conclusion without current court and FDA records

A commercial program should separate three forms of protection:

1. Orange Book-listed patents that can trigger Paragraph IV litigation.
2. Unlisted patents that may support separate infringement claims but do not create the same ANDA stay mechanism.
3. Trade-secret protection for polymer specifications, process controls, coating conditions, drying parameters, and packaging.

For an old product such as CERVIDIL, trade secrets and manufacturing know-how may be more commercially relevant than basic composition patents.

Which companies are challenging CERVIDIL?

The commercial field is likely to include generic-drug manufacturers with experience in vaginal dosage forms, controlled-release polymers, hospital products, or obstetric medicines. A definitive list of active challengers requires current FDA ANDA records, Orange Book data, and litigation dockets.

The most relevant competitor categories are:

• Large generic manufacturers with hospital formularies.
• Specialty generic companies focused on complex dosage forms.
• Contract development and manufacturing organizations with polymer-insert capabilities.
• Obstetric product suppliers pursuing bundled induction products.
• International manufacturers seeking U.S. entry through an ANDA or 505(b)(2) pathway.

The strongest competitor will not necessarily have the lowest API cost. It will have reproducible release performance, dependable supply, and a regulatory package that minimizes clinical uncertainty.

How strong is the CERVIDIL patent estate?

The historical patent estate is likely weaker than the formulation and regulatory barriers. Dinoprostone is an established molecule, and the commercial product has been marketed for decades. Basic active-ingredient protection is not the principal barrier to entry.

The stronger protection points are likely to be:

• Proprietary polymer grade and matrix architecture.
• Specific release-rate behavior.
• Insert geometry and retrieval design.
• Manufacturing sequence and drying conditions.
• Packaging configuration.
• Clinical-use workflow and labeling.

A patent that claims a broad dinoprostone vaginal insert may face validity and obviousness pressure after extensive prior art. A narrowly drafted claim directed to a specific polymer ratio, release profile, or structural feature may be more defensible but easier for a competitor to design around.

What formulation patents could protect a follow-on CERVIDIL product?

A new product could seek protection around a defined technical improvement rather than the basic drug. Potential claim areas include:

• A polymer matrix producing a specified release range.
• Reduced initial burst release.
• Improved stability under elevated humidity.
• A retrieval system with defined removal force.
• A bioadhesive or non-bioadhesive vaginal insert.
• A self-removing or time-limited delivery system.
• A lower-residue formulation.
• A package that improves stability without refrigeration.
• A manufacturing process that improves content uniformity.

Patent value depends on whether the claim captures a clinically meaningful and difficult-to-design-around feature. Broad claims to ordinary hydrogel polymers are likely to face substantial prior art. Narrow claims supported by comparative release, stability, and usability data have greater licensing and enforcement value.

What commercial opportunities exist beyond a generic CERVIDIL insert?

Hospital procurement

Hospitals value reliable supply, predictable removal, low nursing burden, and reduced waste. A product with a simpler storage requirement, clearer retrieval instructions, or improved unit-dose packaging could gain share even with limited formulation differentiation.

Combination products

A company could develop an induction-of-labor kit containing the insert, retrieval documentation, a procedure tray, and electronic administration records. The product would need to preserve the drug's approved use and comply with combination-product requirements.

International markets

Outside the United States, dinoprostone products may be supplied as gels, tablets, inserts, or other vaginal dosage forms. A manufacturer could use CERVIDIL-compatible technology to enter markets where hospitals prefer controlled-release inserts but procurement is price-sensitive.

Licensing

Licensing targets may include:

• Polymer delivery platforms.
• Vaginal dosage-form manufacturing technology.
• Retrieval-device designs.
• Stability-enhancing packaging.
• Regional distribution rights.
• Contract manufacturing capacity.

A platform license is most attractive when it solves a documented equivalence or scale-up problem. A broad license to an unvalidated polymer concept has lower value than access to a manufacturing process with established release and stability data.

What revenue exposure and market dynamics affect CERVIDIL?

CERVIDIL is used in hospitals and labor-and-delivery units, making institutional contracting more important than retail prescribing. Demand is linked to induction-of-labor volume, obstetric admission rates, hospital formularies, and the relative use of dinoprostone versus mechanical methods, misoprostol, or dinoprostone gel.

Competitive pressure comes from:

• Misoprostol, which is inexpensive but used under different dosing and clinical protocols.
• Mechanical cervical-ripening devices.
• Dinoprostone vaginal gels or tablets.
• Hospital-specific induction pathways.
• Generic or authorized-generic vaginal inserts.

The commercial opportunity is therefore a price-volume opportunity with operational differentiation. A new entrant that only discounts price may face rapid margin compression. A product that reduces preparation time, improves storage, or provides dependable supply can defend a higher contract value.

What generic launch scenarios exist for CERVIDIL?

Scenario 1: Direct generic substitution

The entrant matches the reference product's strength, dosage form, release characteristics, retrieval design, and labeling. This is the lowest commercial-risk pathway but requires strong pharmaceutical-equivalence evidence.

Scenario 2: Design-around generic

The entrant uses a different polymer system or insert geometry. This may avoid patent claims but can increase regulatory and clinical-development requirements.

Scenario 3: 505(b)(2) differentiated product

A modified release profile, different retrieval system, or new packaging configuration could support a 505(b)(2) strategy if the product is not suitable for an ANDA. The pathway may support differentiation but usually requires more development capital.

Scenario 4: Non-U.S. launch

A manufacturer launches a dinoprostone insert in selected international markets before pursuing the United States. This can generate manufacturing experience but does not eliminate U.S. equivalence requirements.

Key Takeaways

• CERVIDIL's commercial differentiation comes from controlled release, not dinoprostone novelty.
• The most important excipient issue is polymer-matrix performance, including hydration, diffusion, mechanical integrity, and burst control.
• A Q1/Q2-oriented generic strategy offers the clearest path to an ANDA, but polymer specifications may be difficult to reproduce exactly.
• Packaging, moisture control, retrieval performance, and manufacturing process control are major sources of product quality and patent value.
• Original CERVIDIL exclusivity is historical and expired; current Orange Book listings and later patents determine Paragraph IV exposure.
• The most credible commercial opportunities are hospital-focused generic entry, improved packaging, retrieval-system differentiation, combination induction kits, and international licensing.
• A differentiated 505(b)(2) product could command greater value but would require a larger regulatory and clinical investment.
• Manufacturing know-how may create a stronger practical barrier than broad active-ingredient or basic formulation patents.

FAQs About CERVIDIL Excipient and Commercial Strategy

Is CERVIDIL a hydrogel formulation?

Yes. CERVIDIL is a controlled-release vaginal insert built around a hydrogel delivery system that releases dinoprostone over time.[1]

Can a generic CERVIDIL product use different excipients?

Potentially. A generic product can use different excipients if it satisfies FDA requirements for pharmaceutical equivalence, therapeutic equivalence, safety, quality, and release performance. Different excipients can increase regulatory risk.

Is dinoprostone itself still patent protected?

The original dinoprostone molecule is not the principal exclusivity barrier for CERVIDIL. The relevant issues are any later formulation, device, method-of-use, or manufacturing patents.

Does CERVIDIL require refrigeration?

Storage requirements are governed by the current FDA-approved labeling and package configuration. Packaging development should focus on maintaining polymer and dinoprostone stability under labeled hospital storage conditions.[1]

What is the most valuable intellectual property in a CERVIDIL follow-on product?

The highest-value IP is likely to cover a reproducible release profile, a technically distinct polymer matrix, improved stability, a retrieval system, or a manufacturing process that materially improves scale-up and content uniformity.

References

1. Ferring Pharmaceuticals Inc. (2023). CERVIDIL (dinoprostone) vaginal insert prescribing information. U.S. Food and Drug Administration labeling repository.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug product and approval history records for NDA 020656. FDA Drugs@FDA database.

4. U.S. Food and Drug Administration. (2022). Guidance for industry: Bioavailability and bioequivalence studies submitted in support of abbreviated new drug applications. FDA.

5. U.S. Food and Drug Administration. (2023). Inactive Ingredient Database. FDA.